FullText URL fulltext.pdf
Author Janisch, Florian| Abufaraj, Mohammad| Fajkovic, Harun| Kimura, Shoji| Iwata, Takehiro| Nyirady, Peter| Rink, Michael| Shariat, Shahrokh F.|
Keywords Disease management Primary urethral carcinoma Prognosis Therapy Treatment
Published Date 2019-07-13
Publication Title European Urology Focus
Volume volume5
Issue issue5
Publisher Elsevier
Start Page 722
End Page 734
ISSN 24054569
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2019 European Association of Urology. Published by Elsevier B.V.
File Version publisher
PubMed ID 31307949
DOI 10.1016/j.euf.2019.07.001
Web of Science KeyUT 000490140000008
Related Url isVersionOf https://doi.org/10.1016/j.euf.2019.07.001
FullText URL fulltext.pdf
Author Wada, Koichiro| Araki, Motoo| Tanimoto, Ryuta| Sadahira, Takuya| Watari, Shogo| Maruyama, Yuki| Mitsui, Yosuke| Nakajima, Hirochika| Acosta, Herik| Katayama, Satoshi| Iwata, Takehiro| Nishimura, Shingo| Takamoto, Atsushi| Sako, Tomoko| Edamura, Kohei| Kobayashi, Yasuyuki| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo|
Keywords Photodynamic diagnosis 5-Aminolevulinic acid ALA-PDD Upper urinary tract urothelial carcinoma VISERA ELITE video system
Published Date 2021-03-25
Publication Title BMC urology
Volume volume21
Issue issue1
Publisher BMC
Start Page 45
ISSN 1471-2490
NCID AA12035460
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © The Author(s) 2021.
File Version publisher
PubMed ID 33765999
NAID 120007008530
DOI 10.1186/s12894-021-00819-2
Web of Science KeyUT 000632906900001
Related Url isVersionOf https://doi.org/10.1186/s12894-021-00819-2
JaLCDOI 10.18926/AMO/62810
FullText URL 75_6_705.pdf
Author Iwata, Takehiro| Maruyama, Yuki| Kawada, Tatsushi| Sadahira, Takuya| Katayama, Satoshi| Takamoto, Atsushi| Sako, Tomoko| Wada, Koichiro| Edamura, Kohei| Kobayashi, Yasuyuki| Araki, Motoo| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo|
Abstract Optimal neoadjuvant hormone therapy (NHT) for reducing prostate cancer (PC) patients’ prostate volume pre-brachytherapy is controversial. We evaluated the differential impact of neoadjuvant gonadotropin-releasing hormone (GnRH) antagonist versus agonist on post-brachytherapy testosterone recovery in 112 patients treated pre-brachytherapy with NHT (GnRH antagonist, n=32; GnRH agonists, n=80) (Jan. 2007-June 2019). We assessed the effects of patient characteristics and a GnRH analogue on testosterone recovery with logistic regression and a propensity score analysis (PSA). There was no significant difference in the rate of testosterone recovery to normal levels (> 300 ng/dL) between the GnRH antagonist and agonists (p=0.07). The GnRH agonists induced a significantly more rapid testosterone recovery rate at 3 months post-brachytherapy versus the GnRH antagonist (p<0.0001); there was no difference in testosterone recovery at 12 months between the GnRH antagonist/agonists (p=0.8). In the multivariate analysis, no actor was associated with testosterone recovery. In the PSA, older age and higher body mass index (BMI) were significantly associated with longer testosterone recovery. Post-brachytherapy testosterone recovery was quicker with the neoadjuvant GnRH agonists than the antagonist, and the testosterone recovery rate was significantly associated with older age and higher BMI. Long-term follow-ups are needed to determine any differential effects of GnRH analogues on the quality of life of brachytherapy-treated PC patients.
Keywords testosterone recovery GnRH antagonist GnRH agonist brachytherapy prostate cancer
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2021-12
Volume volume75
Issue issue6
Publisher Okayama University Medical School
Start Page 705
End Page 711
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders Copyright Ⓒ 2021 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 34955538
Web of Science KeyUT 000735297900006
NAID 120007180282
JaLCDOI 10.18926/AMO/62820
FullText URL 75_6_763.pdf
Author Iwata, Takehiro| Sadahira, Takuya| Maruyama, Yuki| Sekito, Takanori| Yoshinaga, Kasumi| Watari, Shogo| Nagao, Kentaro| Kawada, Tatsushi| Tominaga, Yusuke| Nishimura, Shingo| Takamoto, Atsushi| Sako, Tomoko| Edamura, Kohei| Kobayashi, Yasuyuki| Araki, Motoo| Ishii, Ayano| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo| Wada, Koichiro|
Abstract The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.
Keywords genitourinary tract infections fluoroquinolone resistance extended-spectrum beta-lactamase
Amo Type Clinical Study Protocol
Publication Title Acta Medica Okayama
Published Date 2021-12
Volume volume75
Issue issue6
Publisher Okayama University Medical School
Start Page 763
End Page 766
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders Copyright Ⓒ 2021 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 34955548
Web of Science KeyUT 000735319800006
NAID 120007180272